Stocks › ARQT

Arcutis Biotherapeutics, Inc.

ARQT·Nasdaq·United States United States·USD
$26.36
-0.81 (-2.98%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ARQT
Arcutis Biotherapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ARQTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ARQT by members of U.S. Congress · 6 on record · 3 in the last 12 months
All congressional trades →

Whale Activity

Position changes in ARQT reported for 2026-09-30 by 332 institutional filers
Increased: 122New: 59Held: 34Decreased: 67Closed: 38No prior filing: 12
  • Increased122
  • New59
  • Held34
  • Decreased67
  • Closed38
  • No prior filing12
FilerSharesValueChange
BlackRock, Inc.19.2M$506.7Mincreased
MONTANOVA CAPITAL, LLC12.3M$324.3Mdecreased
Frazier Life Sciences Management, L.P.9.9M$261.0Mheld
Rubric Capital Management LP8.4M$222.6Mincreased
STATE STREET CORP7.7M$204.0Mincreased
Polar Capital Holdings Plc6.6M$174.2Mdecreased
UBS Group AG5.5M$146.2Mincreased
MORGAN STANLEY5.3M$140.0Mincreased
VANGUARD CAPITAL MANAGEMENT LLC5.0M$132.0Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC3.8M$100.9Mincreased
BANK OF AMERICA CORP /DE/3.5M$92.3Mincreased
JENNISON ASSOCIATES LLC3.3M$88.1Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ARQT insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -170.3K2025 Q12025 Q2: -44.5K2025 Q22025 Q3: -132.8K2025 Q32025 Q4: -340.9K2025 Q42026 Q1: -211.3K2026 Q12026 Q2: -40.9K2026 Q22026 Q3: -90.4K2026 Q32026 Q4: -56.0K2026 Q4

Recent Insider Transactions

689 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Welgus Howard G.Director · Director Sale −4,728 $28.16 $133K Nov 16, 2026 Form 4 ↗
Matsuda MasaruEVP, Chief Legal Officer Sale −40.0K $34.32 $1.4M Nov 4, 2026 Form 4 ↗
Matsuda MasaruEVP, Chief Legal Officer Sale −1,219 $31.86 $39K Nov 2, 2026 Form 4 ↗
Burnett PatrickEVP, Chief Medical Officer Sale −943 $31.86 $30K Nov 2, 2026 Form 4 ↗
Watanabe ToddSee Remarks · Director Sale −4,377 $31.86 $139K Nov 2, 2026 Form 4 ↗
Welgus Howard G.Director · Director Sale −4,728 $26.93 $127K Oct 15, 2026 Form 4 ↗
Matsuda MasaruSee Remarks Sale −3,674 $25.00 $92K Sep 16, 2026 Form 4 ↗
Welgus Howard G.Director Sale −4,730 $24.18 $114K Sep 15, 2026 Form 4 ↗
Welgus Howard G.Director Option exercise +2,255 $8.63 $19K Sep 15, 2026 Form 4 ↗
Welgus Howard G.Director Option exercise +1,019 $7.51 $8K Sep 15, 2026 Form 4 ↗
Welgus Howard G.Director Option exercise +822 $6.52 $5K Sep 15, 2026 Form 4 ↗
Matsuda MasaruSee Remarks Sale −9,989 $25.03 $250K Sep 8, 2026 Form 4 ↗
Curran TerrieDirector Sale −27.1K $25.03 $677K Aug 27, 2026 Form 4 ↗
Curran TerrieDirector Option exercise +27.1K $8.63 $233K Aug 27, 2026 Form 4 ↗
Curran TerrieDirector Sale −11.1K $25.03 $279K Aug 27, 2026 Form 4 ↗
Curran TerrieDirector Option exercise +11.1K $7.51 $84K Aug 27, 2026 Form 4 ↗
Curran TerrieDirector Sale −1,072 $26.04 $28K Aug 20, 2026 Form 4 ↗
Curran TerrieDirector Option exercise +1,072 $7.51 $8K Aug 20, 2026 Form 4 ↗
Burnett PatrickSee Remarks Sale −1,697 $27.00 $46K Aug 19, 2026 Form 4 ↗
Welgus Howard G.Director Sale −4,730 $26.18 $124K Aug 17, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ARQT · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.6M$93.5M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
2.9M$77.0M0.09%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
2.9M$76.4M0.71%Jun 30, 2026
Small Cap Growth Fund
American Century Mutual Funds, Inc.
1.5M$39.4M0.71%Jul 31, 2026
PGIM Jennison Small Company Fund
Prudential Jennison Small Co Fund, Inc.
1.4M$36.3M1.04%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.3M$34.3M0.04%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.3M$33.6M0.10%Jul 31, 2026
Oberweis Small-Cap Opportunities Fund
OBERWEIS FUNDS
1.2M$31.8M1.12%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
1.1M$27.7M0.18%Jun 30, 2026
BARON DISCOVERY FUND
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)
867.4K$22.7M1.24%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list ARQT's shares (CUSIP 03969K108), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.7M shares6.1%
    Nov 10, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 17.8M shares14.1%
    Oct 5, 2026 · ↗
  • Polar Capital LLPSCHEDULE 13G · passive (13G) · 6.6M shares5.3%
    Aug 14, 2026 · ↗
  • Polar Capital Holdings PlcSCHEDULE 13G · passive (13G) · 6.6M shares5.3%
    Aug 14, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 5.8M shares4.7%
    Aug 7, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 6.3M shares5.1%
    May 12, 2026 · ↗
  • PRUDENTIAL FINANCIAL INCSCHEDULE 13G/A · passive (13G) · 5.3M shares4.3%
    May 8, 2026 · ↗
  • Jennison Associates LLCSCHEDULE 13G/A · passive (13G) · 5.0M shares4.0%
    May 6, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming arcutis biotherapeutics as client
$0$5K$10K$15K$20K2026 Q3: $15K2026
  • JEFFREY J. KIMBELL & ASSOCIATES, INC.ARCUTIS BIOTHERAPEUTICS, INC. · 2026 Q3 · HCR$15K
    Filing ↗
  • JEFFREY J. KIMBELL & ASSOCIATES, INC.ARCUTIS BIOTHERAPEUTICS, INC. · 2026 Q3 · TAR—
    Filing ↗

Government Contracts

Federal awards to Arcutis Biotherapeutics, Inc. · USAspending

No federal contract awards found for Arcutis Biotherapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Arcutis Biotherapeutics, Inc.

No USPTO patent applications found for Arcutis Biotherapeutics, Inc..

Annual Financials

From ARQT's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$376.1M$196.5M$59.6M$3.7Mn/a
Operating income-$12.2M-$128.4M-$241.1M-$301.6M-$206.5M
Net income-$16.1M-$140.0M-$262.1M-$311.5M-$206.4M
Diluted EPS-$0.13-$1.16-$3.78-$5.66-$4.18
Operating cash flow-$5.6M-$112.2M-$247.1M-$257.7M-$174.6M
Cash and equivalents$42.9M$71.3M$88.4M$53.6M$96.4M
Total assets$433.0M$348.9M$341.4M$449.3M$408.2M
Total liabilities$243.5M$191.3M$252.7M$239.7M$110.5M
Shareholders' equity$189.5M$157.5M$88.7M$209.6M$297.7M

As Arcutis Biotherapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in ARQT's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureOct 28, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 5.02, 9.01Results of operations · Officer / director changeAug 5, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 16, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 8.01, 9.01Shareholder vote · Other eventsJun 9, 2026
    EDGAR ↗
  • 8-K · Items 9.01May 6, 2026
    EDGAR ↗

About Arcutis Biotherapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWESTLAKE VILLAGE, CA
IncorporatedDE
Former namesArcutis, Inc.